...the company chose to spin out its CellScreen target screening technology into functional genomics play Inoxell A/S... ...its own pipeline, but this business model was too far away for Inoxell. And as Inoxell... ...to buy Inoxell or its assets." In March of this year, PHARMX decided to close Inoxell...
...said allows both of them the freedom to operate their businesses. In addition, RIGL granted Inoxell... ...target identification technology. Inoxell is an 83% owned subsidiary of Pharmexa A/S (CSE:PHARMX, Horsholm, Denmark). Inoxell A/S...
...To solve this issue Danish pharmaccine company Pharmexa A/S recently spun out functional genomics play Inoxell A/S... ...Phase I/II trials to treat cancer cachexia with partner Ferring Group (Malmo, Sweden). By contrast, Inoxell's... ...we can actually identify what gene causes the phenotype shift," said MEBIO CEO Soren Mouritsen. Inoxell...
Inoxell A/S , Horsholm, Denmark Business: Genomics Hired: Peter Kristensen as CEO, formerly vice president of project management at Novo Nordisk A/S ; and Jacob Sten Petersen as CSO, formerly a department head in the target...
...Pharmexa, formerly M&E Biotech, spun out its CellScreen technology into a separate company called Inoxell. CellScreen... ...Dansk Erhvervsinvestering each hold 8.3% of Inoxell after investing DKK7.5 million each. Pharmexa transferred to Inoxell... ...MEBIO plans to focus on its AutoVac therapeutic vaccine technology. Pharmexa A/S (CSE:MEBIO), Horsholm, Denmark Inoxell A/S...
...Pharmexa (CSE:MEBIO), formerly M&E Biotech, has spun out a new genomics company Inoxell , based on... ...for identification of validated targets by genetic manipulation of intracellular processes. MEBIO owns 83.3% of Inoxell... ...each. Pharmexa has transferred to Inoxell a research deal with AstraZeneca (see BioCentury, Jan. 2). Inoxell...
...the company chose to spin out its CellScreen target screening technology into functional genomics play Inoxell A/S... ...its own pipeline, but this business model was too far away for Inoxell. And as Inoxell... ...to buy Inoxell or its assets." In March of this year, PHARMX decided to close Inoxell...
...said allows both of them the freedom to operate their businesses. In addition, RIGL granted Inoxell... ...target identification technology. Inoxell is an 83% owned subsidiary of Pharmexa A/S (CSE:PHARMX, Horsholm, Denmark). Inoxell A/S...
...To solve this issue Danish pharmaccine company Pharmexa A/S recently spun out functional genomics play Inoxell A/S... ...Phase I/II trials to treat cancer cachexia with partner Ferring Group (Malmo, Sweden). By contrast, Inoxell's... ...we can actually identify what gene causes the phenotype shift," said MEBIO CEO Soren Mouritsen. Inoxell...
Inoxell A/S , Horsholm, Denmark Business: Genomics Hired: Peter Kristensen as CEO, formerly vice president of project management at Novo Nordisk A/S ; and Jacob Sten Petersen as CSO, formerly a department head in the target...
...Pharmexa, formerly M&E Biotech, spun out its CellScreen technology into a separate company called Inoxell. CellScreen... ...Dansk Erhvervsinvestering each hold 8.3% of Inoxell after investing DKK7.5 million each. Pharmexa transferred to Inoxell... ...MEBIO plans to focus on its AutoVac therapeutic vaccine technology. Pharmexa A/S (CSE:MEBIO), Horsholm, Denmark Inoxell A/S...
...Pharmexa (CSE:MEBIO), formerly M&E Biotech, has spun out a new genomics company Inoxell , based on... ...for identification of validated targets by genetic manipulation of intracellular processes. MEBIO owns 83.3% of Inoxell... ...each. Pharmexa has transferred to Inoxell a research deal with AstraZeneca (see BioCentury, Jan. 2). Inoxell...
